Intuitive Surgical, Inc.

Intuitive Surgical earns revenue in three ways: selling da Vinci systems (capital equipment), selling the instruments consumed in each procedure (recurring), and charging annual service contracts on installed systems. The instruments and service lines together make up the majority of revenue and are highly predictable because they grow with every new procedure performed, regardless of whether any new systems are sold that quarter.

That structure makes procedure volume the most important forward-looking metric in any ISRG earnings report. When surgeons perform more minimally invasive procedures using da Vinci — especially newer indications like colorectal and thoracic surgery — the instrument revenue grows organically without additional capital sales. Traders who understand this focus on procedure growth rates in the earnings call, not just total revenue.

ISRG has historically held a broad multi-year trading range, with the $430 level acting as institutional support that has been tested and defended multiple times since late 2024. When ISRG revisits this zone, institutional buying tends to absorb the selling, creating a low-risk setup for longer-timeframe traders who size in near support with a stop below the range. The risk is a genuine fundamental deterioration — a missed procedure guidance or unexpected competitive entry — which has historically not materialized.

On the breakout side, ISRG tends to trend cleanly once it clears major resistance. The stock's high price per share (~$420-600) means percent moves are amplified, and options are active enough to provide defined-risk alternatives for traders who want to participate in the range without holding a $42,000 position at 100 shares.